If both treatments make sense on their own, can I use them together?
Do not assume so. Evidence for a combination applies to the exact treatments, people, supervision, outcomes, and study design tested. Two options may each be reasonable to discuss. Using them together may remain untested, conflict with a label, create too much burden, or be wrong for you. Evidence Evidence Evidence
What is known
- Sources cited, not yet graded
Vitiligo studies test some combinations because the components may affect different parts of the condition or improve a group outcome. Evidence for each component must still be separated from evidence for the exact pair.
What is uncertain
- Depends on you
A study of one cream or light device does not show how every similar product will work. This includes creams in the same class as Protopic (tacrolimus). The study may not show which treatment caused a change or whether it lasted. Whether two treatments can run together is a prescribing decision, and not one to work out on your own.
Questions for the clinicians coordinating the plan
Has this exact combination been studied?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does the HI-Light study apply to me?
It may inform a conversation about the exact supervised combination studied. The trial found better group results with home handheld narrowband UVB plus a steroid cream. Still, only a minority met the success goal. Reactions occurred, and benefits did not reliably last after treatment ended. Evidence
What is known
- Sources cited, not yet graded
The UK trial studied people with localized active vitiligo. It compared defined groups and included participant-reported treatment success. This is stronger evidence for that exact combination and population than before-and-after images without a comparison group.
What is uncertain
- Depends on you
The study does not create a home plan for you. It also leaves gaps about other vitiligo patterns, body areas, ages, skin tones, racial or ethnic groups, countries, creams, devices, and health systems. Its findings still need clinical review and qualified supervision.
Questions for the clinicians coordinating the plan
Do I resemble the people included in HI-Light?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What benefit did HI-Light show?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What reactions and later uncertainty should I understand?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if Protopic (tacrolimus) or Elidel (pimecrolimus) is being combined with light treatment?
Ask both teams to resolve the instructions before you proceed. US labels for tacrolimus and pimecrolimus tell patients to limit or avoid sunlight and ultraviolet treatment. Vitiligo guidelines discuss selected combinations with supervised light therapy. Evidence Evidence Evidence Evidence Evidence
What is known
- Sources cited, not yet graded
A product label and a clinical guideline serve different purposes. Off-label combination research does not erase the approved warning, and the warning alone does not explain every specialist decision. One small double-blinded, placebo-controlled trial added pimecrolimus to supervised light treatment. It reported a difference for selected patches on the face, and not for other body areas.
What is uncertain
- Depends on you
That trial was not established as commercially independent in this review. It does not override the US label warning. It does not establish a benefit for pimecrolimus used on its own, does not generalize to every body site, and does not provide a self-directed combination plan. The prescribing and phototherapy teams must decide whether the proposed combination is justified and provide one set of instructions. Evidence for tacrolimus does not automatically apply to pimecrolimus, and one light-treatment setting cannot stand in for another.
Questions for the clinicians coordinating the plan
How does the current label affect this combination?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who owns the final coordinated instructions?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does the current Opzelura label establish using it with narrowband UVB?
No. The current US label defines ruxolitinib cream’s approved use and ultraviolet-exposure precautions; it does not establish the benefit, safety, or instructions for combining it with narrowband UVB. Evidence
What is known
- Sources cited, not yet graded
The label is authoritative for the approved indication, warnings, and precautions. It does not turn a separately studied or proposed combination into labeled care.
What is uncertain
- Depends on you
Any separate combination study must be reviewed for its exact population, design, outcomes, follow-up, and conflicts with the current label before it can inform a plan.
Questions for the clinicians coordinating the plan
Which parts of this plan are evidence-based or extrapolated?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Who should coordinate my combination plan?
Before proceeding, know what each treatment adds and the evidence for the exact pair. Review label conflicts, major risks, daily effort, and what to track. Confirm which clinician coordinates the plan. Application order, treatment changes, and restart decisions belong there. Evidence Evidence Evidence Evidence Evidence
What is known
- Sources cited, not yet graded
Different clinicians or sites of care can give conflicting written instructions. Make sure both teams have the same current medicine list. Ask who will resolve any disagreement so that task does not fall on you.
What is uncertain
- Depends on you
Coordination cannot guarantee a result or remove every uncertainty. If the evidence, product label, or written instructions conflict, ask the treating team for clarification instead of improvising.
Questions for the clinicians coordinating the plan
What is each treatment supposed to add?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who resolves conflicts in my written instructions?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should I track to separate benefit from harm?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-15.
- What this evidence supports
- Vitiligo studies test some combinations because the components may affect different parts of the condition or improve a group outcome. Evidence for each component must still be separated from evidence for the exact pair.
- What it does not establish
- A study of one cream or light device does not show how every similar product will work. This includes creams in the same class as Protopic (tacrolimus). The study may not show which treatment caused a change or whether it lasted. Whether two treatments can run together is a prescribing decision, and not one to work out on your own.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
It may inform a conversation about the exact supervised combination studied. The trial found better group results with home handheld narrowband UVB plus a steroid cream. Still, only a minority met the success goal. Reactions occurred, and benefits did not reliably last after treatment ended.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
Ask both teams to resolve the instructions before you proceed. US labels for tacrolimus and pimecrolimus tell patients to limit or avoid sunlight and ultraviolet treatment. Vitiligo guidelines discuss selected combinations with supervised light therapy.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
Protopic (tacrolimus) ointment: US prescribing information and Medication Guide (opens in a new tab)
DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product. Its mechanism-of-action section supports that tacrolimus binds FKBP-12 to block calcineurin phosphatase, preventing the T-cell activation that its boxed warning and local-effect data describe. Its local-adverse-reaction data supports burning in roughly 46-58% and itching in roughly 41-46% of studied patients, most often in the first few days and easing as treatment continues. Its Dosage and Administration section supports applying a thin layer twice daily and re-examining the patient if signs and symptoms do not improve within six weeks.
What it does not support
It does not approve tacrolimus for vitiligo or psoriasis, establish efficacy for either, or resolve off-label guideline discussion of supervised combinations. Its dosing and six-week re-examination window are stated for its approved atopic-dermatitis indication, not as a vitiligo-specific schedule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight. This label itself is a generic pimecrolimus cream filing (packager Oceanside Pharmaceuticals, a division of Bausch Health US, LLC), not the original brand Elidel label, so it also supports that a generic pimecrolimus cream is currently marketed. Its Dosage and Administration section supports applying a thin layer twice daily and re-examining the patient if signs and symptoms persist beyond six weeks; its boxed warning separately supports that continuous long-term use should be avoided. Its adult 1-year active-comparator adverse-reaction table (328 pimecrolimus-treated subjects) supports application-site burning in about 25.9%, headache in about 25.4%, nasopharyngitis in about 7.6%, and influenza in about 9.8% of that adult trial population.
What it does not support
It does not approve pimecrolimus for vitiligo or psoriasis, establish efficacy for either, or resolve off-label guideline discussion of supervised combinations. Its dosing and six-week re-examination window, and its adult adverse-reaction percentages, are stated for its approved atopic-dermatitis indication and trial population, not as a vitiligo-specific schedule or vitiligo-trial safety rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It also supports the labeled dosing instruction: "Apply a thin layer of OPZELURA topically twice daily to affected areas of up to 10% body surface area." It further supports the labeled re-evaluation point: "If the patient does not find the repigmentation meaningful by 24 weeks, the patient should be re-evaluated by the healthcare provider." It also supports the vitiligo-trial adverse-reaction rates at 1% incidence or greater: application-site acne 6%, application-site itching 5%, a common-cold-type illness (nasopharyngitis) 4%, headache 4%, urinary tract infection 2%, application-site redness (erythema) 2%, and fever (pyrexia) 1%. It does not guarantee benefit, establish suitability beyond the labeled population, authorize adding phototherapy, or state which reaction should prompt a call to the prescriber beyond directing patients to the Medication Guide and their healthcare provider.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Thomas KS, et al.)Randomized trial · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result. The topical-corticosteroid-alone arm used mometasone furoate 0.1% ointment, applied once daily on alternating weeks for up to 9 months. It supports 17% (20/119) reaching participant-reported treatment success at 9 months, and 3% (4/115) reaching the trial’s stricter blinded-assessed ≥75% repigmentation at 9 months. Skin thinning was reported in 2.5% (13/517) of participants across all trial groups, including one on placebo ointment. Over 40% of participants across all groups reported loss of treatment response by 21 months. It supports that participant-reported treatment success at 9 months was lower for patches on the hands and feet than on other body regions, without publishing an exact per-region percentage in its main results tables. The trial randomized 517 adults and children, aged over 5, with nonsegmental vitiligo covering about 10% or less of body surface area and at least one patch active in the prior 12 months, across 16 UK hospitals.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Dermatological Treatment (Esfandiarpour I, et al.)Randomized trial · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a reported difference for selected facial lesions, but not other body areas, when pimecrolimus was added to supervised light treatment in this small study.
What it does not support
Commercial independence was not established in this review; the study does not override the US label warning, establish monotherapy benefit, generalize to every body site or provide a self-directed combination plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.